ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
Saved in:
| Title: | ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. |
|---|---|
| Authors: | Maithel SK; Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA. smaithe@emory.edu. |
| Source: | Annals of surgical oncology [Ann Surg Oncol] 2023 Oct; Vol. 30 (11), pp. 6567-6568. Date of Electronic Publication: 2023 Jun 29. |
| Publication Type: | Journal Article; Comment |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
